Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Company Overview - Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic targeting soluble amyloid beta oligomers (AβOs) for Alzheimer's disease (AD) treatment [5] - The company is headquartered in Newton, Massachusetts, and is advancing its investigational product candidate, sabirnetug (ACU193), in the ongoing Phase 2 clinical trial ALTITUDE-AD [5] Product Information - Sabirnetug (ACU193) is a humanized monoclonal antibody that selectively targets toxic soluble AβOs, which are believed to be early triggers of Alzheimer's disease pathology [3][5] - The drug has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of early AD [3] Clinical Trial Details - The ALTITUDE-AD study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled trial initiated in 2024, designed to evaluate the efficacy and safety of sabirnetug infusions administered every four weeks [4] - The trial aims to enroll approximately 540 individuals with early Alzheimer's disease, including those with mild cognitive impairment or mild dementia due to AD [4] - The study is currently ongoing at multiple investigative sites across the United States, Canada, the UK, and the European Union [4] Biomarker Utilization - Acumen will present updated data on the use of a validated plasma pTau217 assay as a screening tool for potential participants in the ALTITUDE-AD trial [2] - The pTau217 biomarker indicates AD pathology and is used to identify individuals who qualify for additional amyloid testing [2] Upcoming Presentation - A late-breaking presentation will be held on October 31, 2024, at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference, focusing on the participant screening process in the ALTITUDE-AD study [1][3]